Levofloxacin, as a third-generation fluoroquinolone antibacterial agent, is widely used in respiratory, urinary tract, and skin and soft tissue infections due to its broad-spectrum antibacterial activity and excellent bioavailability.
1 It is a safe and effective medication listed on the World Health Organization WHO Essential Medicines List. However, with the increasing frequency of clinical use, the complexity and potential risks of its adverse events (AE) have gradually become apparent. AE signal mining is crucial for evaluating drug safety.
2 In recent years, research on Levofloxacin-related AE based on the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database has been increasing
[3,4]. However, systematic analysis and risk signal mining of Levofloxacin-related AE using data from domestic drug adverse reaction monitoring centers remain relatively scarce. There is an urgent need to strengthen localized research to improve the drug safety risk assessment system.
Therefore, this study is based on the Adverse Drug Reaction Monitoring Center Database,
3 conducting a retrospective analysis of spontaneous reports of Levofloxacin AE over the past five years. The aim is to understand its occurrence characteristics, combination medication situations, and to explore potential risk signals. Additionally, the study further validates the effectiveness of the identified risk signals by analyzing Levofloxacin-related AE in the FAERS database, with the goal of providing references for its clinical safe use.
1 Data and methods
1.1 Data sources
Extract all spontaneous reports of Levofloxacin AE received by the Adverse Drug Reaction Monitoring Center Database
4 from January 2020 to December 2024. All extracted reports have undergone standardized evaluation and assessment. Include spontaneous reports where the “Primary Suspect Drug” field contains “Levofloxacin,” and exclude reports with incomplete or duplicate information. Risk signal validation data is derived from AE reports related to Levofloxacin in the FAERS database from the first quarter of 2004 to the second quarter of 2024, using the English generic name “Levofloxacin” as the search term. Reports where the drug is listed as the primary suspect are included, and duplicate reports are identified and removed based on report information.
1.2 Data processing
The included AE spontaneous reports were standardized and organized according to the included terms (IT), preferred terms (PT), and system organ classes (SOC) of the WHO Adverse Reaction Terminology (WHOART)
5 for the AE names and affected system organs involved in the selected reports.
6 When the same report involves multiple PTs and SOCs, it should be split and calculated separately by case count. Based on this, the original data should be reviewed for the classification of AE severity according to the Common Terminology Criteria for Adverse Events (CTCAE) v5.0.
7 Specifically, a two-stage review by independent evaluators was employed: events with granular clinical data were graded directly, while those lacking such details were operationalized using event outcomes as a severity proxy. The AE report was standardized using the clinical drug nomenclature RxNorm, with PT terms normalized according to the Medical Dictionary for Regulatory Activities (MedDRA) v24.0
8.
1.3 Spontaneous report analysis
The analysis of AE spontaneous reports was conducted using Microsoft Excel 2021 and R 4.4.1 software. Count data were expressed as frequencies and percentages, with intergroup comparisons performed using the
χ2 test. A statistically significant difference was determined when the test result met
P < 0.05. Based on this, the classic Apriori algorithm in association rule analysis was employed to explore drug combination patterns.
91.4 Risk signal detection
The advantages, disadvantages, and application scopes of different signal detection methods based on spontaneous reporting data vary.
10 Among these, the disproportionality analysis method is widely applied in AE signal mining. This study employs the reporting odds ratio (ROR), proportional reporting ratio (PRR), the comprehensive criteria method by the UK Medicines and Healthcare Products Regulatory Agency (MHRA),
11 and the Bayesian Confidence Propagation Neural Network (BCPNN) to detect risk signals. The above four common disproportionality methods detected a target number of AE reports ≥ 3, with the detection thresholds as follows: a. ROR method: ROR 95% confidence interval (CI) lower limit > 1; b. PRR method: PRR 95% CI lower limit
> 1; c. MHRA method: PRR ≥ 2,
χ2 ≥ 4; d. BCPNN method: IC-2SD
> 0. A positive signal was determined based on detection by all the above methods as the positive criterion.
122 Results
According to the inclusion and exclusion criteria, a total of 4,353 Levofloxacin AE reports submitted to the AE monitoring system in the past five years were screened for this study. Among them, there were 311 cases of severe AE (accounting for 7.14%) and 4,042 cases of general AE (accounting for 92.86%).
2.1 General patient information
In the 4,353 reports of AE caused by Levofloxacin, there were 2,443 male patients (56.12%) and 1,897 female patients (43.58%), with a male-to-female ratio of 1.29:1. The patients' ages ranged from [0, 120], with a median age of 57. The age distribution of female patients approximated a normal distribution, while the highest concentration of male patients fell within the [20, 30) age range (see Fig. 1). Among all reports, 380 patients (8.73%) had a prior history of AE.
2.2 Medication usage
A total of 4,357 medication records related to Levofloxacin preparations were involved in the 4,353 AE reports. This includes 4 cases where patients sequentially or concurrently used two or more Levofloxacin preparations. Among these, 3 patients switched from Levofloxacin injection to oral dosage forms, and 1 patient concurrently used Levofloxacin injection and eye drops.
2.2.1 Dosage forms
The primary dosage form of Levofloxacin was injection, accounting for 3,985 cases (91.46%), followed by tablets with 194 cases (4.45%), drops with 163 cases (3.74%), ophthalmic gel with 7 cases (0.16%), capsules with 4 cases (0.09%), and ear drops with 4 cases (0.09%), as shown in Fig. 2.
The chart visualizes the proportion of different dosage forms associated with adverse events. Each square represents a unit of the total reports.
2.2.2 Reason for medication
The primary reasons for patient medication were respiratory system infections (including diagnoses such as lung infections, pneumonia, upper respiratory tract infections, etc.), genitourinary system infections, skin and soft tissue infections, and digestive system infections. There were 38 cases where the reason for medication or the specific site of infection was not specified.
2.2.3 Drug combination
Out of 4,353 AE reports related to Levofloxacin, a total of 575 reports involved drug combinations, accounting for 13.21%. Among these, 402 reports involved the combination of 2 drugs, 116 reports involved 3 drugs, 41 reports involved 4 drugs, 11 reports involved 5 drugs, and 5 reports involved combinations of 6 or more drugs. On this basis, an association rule analysis was conducted on all records of combined drug use using the Apriori algorithm, with the support set at ≥ 0.01 and confidence at ≥ 0.6, resulting in 11 association rules (see Table 1). These rules were then sorted in descending order and subjected to visual analysis (Fig. 3).
2.3 AE involved system organs, clinical manifestations, and outcomes
In 4,353 cases of AE induced by Levofloxacin, the primary SOC involved were skin and appendages disorders (1,768 cases, accounting for 35.33%), gastrointestinal system disorders (730 cases, accounting for 14.58%), and vascular, hemorrhagic, and coagulation disorders (564 cases, accounting for 11.27%). The clinical manifestations predominantly included Rash (763 cases, accounting for 15.25%), Pruritus (721 cases, accounting for 14.41%), and Phlebitis (394 cases, accounting for 7.87%), as detailed in Table 2. Among all patients who experienced AE, 4,212 cases (96.76%) improved or recovered, 50 cases showed no improvement, 1 case resulted in death, and the outcome was unknown for 90 cases.
2.4 Risk signal mining
A systematic organ-level risk signal mining was conducted for Levofloxacin-related AE, identifying a total of 5 positive risk signals. Ranked by signal strength from highest to lowest, these signals were: administration site conditions (ROR = 4.98), visual disorders (ROR = 2.87), Skin and appendages disorders (ROR = 2.26), vascular, hemorrhagic, and clotting disorders (ROR = 1.92), and psychiatric disorders (ROR = 1.65), as shown in Fig. 4. Further in-depth analysis of the 208 PTs involved in AE identified 40 statistically significant risk signals based on four disproportionality methods. External validation using Levofloxacin-related AE report data from the FAERS database ultimately yielded 27 positive signals. The three PTs with the highest signal strength were infusion site pruritus (ROR = 39.77), tendonitis (ROR = 32.4), and infusion site rash (ROR = 24.16), as shown in Table 3.
3 Discussion
3.1 The influence of patient gender and age on Levofloxacin AE
In this study, the male-to-female ratio of patients reporting AEs associated with Levofloxacin was 1.29:1. However, some scholars have pointed out that female patients generally have relatively weaker immune function, lower renal clearance rates, and greater sensitivity to drugs. AE reports involving females are typically more frequent than those involving males.
15 Most previous studies have indicated that in AEs associated with induced by Levofloxacin, females usually account for a slightly higher proportion than males.
16 This discrepancy may be related to the occupational characteristics of the medication-using population within this monitoring system or could be influenced by factors such as sample selection and reporting biases inherent to spontaneous reporting systems. Furthermore, this study included patients with a wide age range, spanning from 0 to 120 years. However, current research findings on the relationship between Levofloxacin AEs and factors such as age and gender remain inconsistent. Future studies could incorporate detailed information on patient demographics, medication usage patterns, and occupational distribution to conduct more in-depth investigations. This would help clarify the patterns and potential associations by which factors like gender and age influence the reporting or occurrence of Levofloxacin AEs. It is noteworthy that in this study, 380 patients had a prior history of AE. Patients with a history of AE may face an increased potential for recurrence, highlighting the need for clinicians to exercise heightened vigilance when prescribing medications to such individuals.
17 Close monitoring of drug responses is essential to enhance patient safety.
3.2 The impact of drug dosage forms and drug combinations on Levofloxacin AE
Within the study scope, injections were the primary dosage form associated with Levofloxacin AEs, which may be related to the clinical strategy of frequently using Levofloxacin injections for treating severe infections.
18 The disproportionate reporting of AEs associated with injectable formulations may be related to their rapid onset of action and high bioavailability, but it could also lead to greater fluctuations in drug concentration due to direct entry into the bloodstream, potentially contributing to adverse outcomes. Additionally, the excipients in these injectables may cause local irritation.
19 It is noteworthy that 4 patients had instances of repeated or mixed use of different dosage forms of Levofloxacin. Such medication patterns may lead to cumulative drug exposure, particularly requiring vigilance for drug accumulation in patients with renal insufficiency. In this study, 380 Levofloxacin AE reports involved co-medications. The association rule analysis results indicated that the combination of cephalosporin injectables (such as cefoperazone sodium and sulbactam sodium, or ceftazidime) with Levofloxacin showed relatively high support and confidence levels. Cephalosporins exert their antibacterial effects by inhibiting bacterial cell wall synthesis, while Levofloxacin interferes with bacterial DNA synthesis and replication by inhibiting DNA gyrase. Although clinical studies
[20,21] have shown that the combination of these two drugs can effectively improve clinical symptoms and enhance treatment efficacy, a potential association with adverse outcomes during their combined use cannot be ruled out. Therefore, it is recommended to conduct a careful evaluation before clinical co-administration.
3.3 Major system organs affected by Levofloxacin AE and statistical signals
In this study, which included 4,353 reports of AE associated with Levofloxacin, Skin and appendages disorders were the most frequently SOC, consistent with previous research findings.
22 From the perspective of clinical manifestations, skin symptoms such as rashes and itching exhibit notable disproportionate reporting. From a potential immunological mechanism perspective,
23 Levofloxacin may trigger IgE cross-reactivity, activating mast cells or basophil granulocytes within the skin connective tissue. This activation promotes the degranulation of Mas-related G protein-coupled receptor X2, rapidly releasing inflammatory mediators such as histamine, bradykinin, and PAF.
24 These mediators stimulate capillary endothelial cells in the skin, inducing vasodilation and increased vascular permeability, which subsequently leads to a decrease in effective circulating blood volume. Consequently, this cascade may result in typical skin damage manifestations such as rashes and itching
[25-26]. In signal detection analysis, skin and appendages disorders (ROR = 2.26) ranked third among positive statistical signals, while skin-related PTs such as rash and pruritus demonstrated significant signal strength. This consistency in multidimensional assessment further reinforces the potential association between Levofloxacin and the Skin and appendages disorders. Furthermore, we cannot ignore the potential association between the dosage form and the emergence of application site disorders as the strongest SOC-level signal. Given that 91.46% of the included reports involved injections,it is plausible that this prominence is partially attributable to local reactions inherent to the parenteral administration route.
4 Conclusion
This study systematically analyzed the spontaneous AE reports associated with Levofloxacin from the Adverse Drug Reaction Monitoring Center Database over a five-year period, and further cross-validated the positive signals identified via disproportionality algorithms using data from the FAERS database. The findings confirm that the identified signals align closely with the established safety profile, with skin and appendages disorders being the most frequently affected SOC and administration site reactions presenting the strongest statistical signals. Clinically, it is recommended to conduct a thorough evaluation before combining cephalosporin injectables with Levofloxacin. While disproportionality analysis generates statistical hypotheses rather than biological causality, these robust real-world data reinforce the necessity for vigilant monitoring. Future research should integrate prospective cohort studies to further verify these associations, particularly for combination therapies, and explore personalized regimens to mitigate AE incidence.
2026 Publishing services by Elsevier B.V. on behalf of Higher Education Press and KeAi Communications Co. Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).